Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Drugs of Today

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1358/DOT.2006.42.1.963528PMID 16511610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.

  2020cited by this paper
• Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation

  2005cited by this paper
• Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects

  2004cited by this paper
• The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element*

  2003cited by this paper
• Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice*

  2003cited by this paper
• Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations Published, JLR Papers in Press, November 4, 2002. DOI 10.1194/jlr.M200414-JLR200

  2003cited by this paper
• Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators*

  2003cited by this paper
• Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse.

  2003cited by this paper
• Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor &agr; Reduces Cholesterol Esterification in Macrophages

  2003cited by this paper
• Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.

  2002cited by this paper
• Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice*

  2002cited by this paper
• The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese.

  2002cited by this paper
• Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.

  2002cited by this paper
• Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression

  2001cited by this paper
• Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators.

  2001cited by this paper
• An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing

  2001cited by this paper
• Regulation and intracellular trafficking of the ABCA1 transporter.

  2001cited by this paper
• Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate*

  2001cited by this paper
• Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene.

  2001cited by this paper
• Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule.

  2001cited by this paper
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

  2001cited by this paper
• Relationship between Expression Levels and Atherogenesis in Scavenger Receptor Class B, Type I Transgenics*

  2000cited by this paper
• CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors.

  2000cited by this paper
• Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial.

  2000cited by this paper
• Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse.

  2000cited by this paper
• PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

  2000cited by this paper
• Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease: The Copenhagen City Heart Study

  2000cited by this paper
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

  2000cited by this paper
• Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study.

  2000cited by this paper
• Megalin Acts in Concert with Cubilin to Mediate Endocytosis of High Density Lipoproteins*

  2000cited by this paper
• Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.

  1999cited by this paper
• Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice*

  1999cited by this paper
• Cubilin, the endocytic receptor for intrinsic factor-vitamin B(12) complex, mediates high-density lipoprotein holoparticle endocytosis.

  1999cited by this paper
• Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of pparalpha transcriptional activity mediated by stat5b.

  1999cited by this paper
• Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.

  1999cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• DNA sequences responsible for reduced promoter activity of human phospholipid transfer protein by fibrate.

  1999cited by this paper
• The intrinsic factor–vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein

  1999cited by this paper
• High density lipoprotein receptors, binding proteins, and ligands.

  1999cited by this paper
• Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.

  1998cited by this paper
• Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

  1998cited by this paper
• Peroxisome proliferator-activated receptors gamma and alpha mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression.

  1998cited by this paper
• Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration.

  1998cited by this paper
• Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.

  1998cited by this paper
• The Nuclear Receptors Peroxisome Proliferator-activated Receptor α and Rev-erbα Mediate the Species-specific Regulation of Apolipoprotein A-I Expression by Fibrates*

  1998cited by this paper
• Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in Aging*

  1998cited by this paper
• Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol.

  1998cited by this paper
• Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.

  1998cited by this paper
• Hyperalphalipoproteinemia: characterization of a cardioprotective profile associating increased high-density lipoprotein2 levels and decreased hepatic lipase activity.

  1998cited by this paper
• Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.

  1998cited by this paper
• A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.

  1998cited by this paper
• A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear hormone receptor PPARα

  1998cited by this paper
• Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

  1998cited by this paper
• Fatty Acids Activate Transcription of the Muscle Carnitine Palmitoyltransferase I Gene in Cardiac Myocytes via the Peroxisome Proliferator-activated Receptor α*

  1998cited by this paper
• Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor*

  1998cited by this paper
• Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner.

  1998cited by this paper
• Hepatic lipase deficiency.

  1998cited by this paper
• Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels

  1997cited by this paper
• Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

  1997cited by this paper
• Hepatic Lipase Deficiency Increases Plasma Cholesterol but Reduces Susceptibility to Atherosclerosis in Apolipoprotein E-deficient Mice*

  1997cited by this paper
• Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.

  1997cited by this paper
• Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha-migrating high-density lipoprotein particles.

  1997cited by this paper
• Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).

  1997cited by this paper
• Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux*

  1997cited by this paper
• Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice*

  1997cited by this paper
• A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism.

  1997cited by this paper
• Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

  1996cited by this paper
• Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.

  1996cited by this paper
• Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.

  1996cited by this paper
• Defective forebrain development in mice lacking gp330/megalin.

  1996cited by this paper
• PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.

  1996cited by this paper
• Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.

  1996cited by this paper
• The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.

  1996cited by this paper
• Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor

  1996cited by this paper
• Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma.

  1996cited by this paper
• Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools.

  1995cited by this paper
• Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.

  1995cited by this paper
• Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

  1995cited by this paper
• Presence and formation of 'free apolipoprotein A-I-like' particles in human plasma.

  1995cited by this paper
• Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E.

  1995cited by this paper
• Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase.

  1995cited by this paper
• Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between Jun and peroxisome proliferator-activated receptor alpha.

  1995cited by this paper
• Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.

  1995cited by this paper
• Molecular physiology of reverse cholesterol transport.

  1995cited by this paper
• Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.

  1995cited by this paper
• Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

  1995cited by this paper
• Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.

  1994cited by this paper
• Dissociation of lipid-free apolipoprotein A-I from high density lipoproteins.

  1994cited by this paper
• Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia

  1994cited by this paper
• Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice.

  1994cited by this paper
• Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

  1994cited by this paper
• Triglyceride‐ and Cholesterol‐Rich Lipoproteins Have a Differential Effect on Mild/Moderate and Severe Lesion Progression as Assessed by Quantitative Coronary Angiography in a Controlled Trial of Lovastatin

  1994cited by this paper
• Quantitation of pre beta-HDL-dependent and nonspecific components of the total efflux of cellular cholesterol and phospholipid.

  1993cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper
• Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma.

  1993cited by this paper
• Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations.

  1993cited by this paper
• Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein

  1993cited by this paper
• Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

  1992cited by this paper
• Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment

  1992cited by this paper

• Lipolysis of host triacylglyceride-rich lipoproteins creates a toxic microenvironment for Staphylococcus aureus

  2026cites this paper
• Effect of saroglitazar on glycaemic parameters: A systematic review and meta‐analysis of randomized controlled trials

  2025cites this paper
• Fenofibrate Reduces Ischemic Cerebral Edema via the Suppression of Aquaporin‐4

  2025cites this paper
• Antioxidant Synergy in a Mixture of Powder Plant Leaves and Effects on Metabolic Profile, Oxidative Status and Intestinal Morpho-Histochemical Features of Laying Hens

  2025cites this paper
• DGK1 as a Target of Gemfibrozil to Induce Lipid Accumulation via the Transcription Factors TUP1/CYC8 in Saccharomyces cerevisiae

  2025cites this paper
• Deciphering the multi-state binding and dissociation of fenofibrate with β-cyclodextrin and its derivatives: Insights from phase solubility analysis and molecular modeling

  2024cites this paper
• Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux

  2023cites this paper
• Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

  2023cites this paper
• Association of plasma metabolites and diagnostic imaging findings with hepatic lipidosis in bearded dragons (Pogona vitticeps) and effects of gemfibrozil therapy

  2023cites this paper
• Disorders of lipid metabolism. Clinical Guidelines 2023

  2023cites this paper
• Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional study

  2023cites this paper
• Clinical features and functions of a novel Lpl mutation C.986A>C (p.Y329S) in patient with hypertriglyceridemia.

  2022cites this paper
• The Symbiosis Between Lactobacillus acidophilus and Inulin: Metabolic Benefits in an Obese Murine Model.

  2022cites this paper
• Nutraceuticals/Drugs Promoting Mitophagy and Mitochondrial Biogenesis May Combat the Mitochondrial Dysfunction Driving Progression of Dry Age-Related Macular Degeneration

  2022cites this paper
• Perfluorooctanoic Acid Induces Liver and Serum Dyslipidemia in Humanized PPARα Mice fed an American Diet

  2021cites this paper
• Oleuropein-Induced Acceleration of Cytochrome P450–Catalyzed Drug Metabolism: Central Role for Nuclear Receptor Peroxisome Proliferator-Activated Receptor α

  2021cites this paper
• Therapeutic Targets, Novel Drugs, and Delivery Systems for Diabetes associated NAFLD and Liver Fibrosis.

  2021cites this paper
• Plasma triacylglycerols are biomarkers of β-cell function in mice and humans

  2021cites this paper
• Linking membrane fluidity with defective antigen presentation in leishmaniasis

  2021cites this paper
• Human Drug Pollution in the Aquatic System: The Biochemical Responses of Danio rerio Adults

  2021cites this paper
• Metabolic Regulation of SARS-CoV-2 Infection

  2021cites this paper
• Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, blocks steatosis and alters the inflammatory response in a mouse model of inflammation-dioxin interaction.

  2021cites this paper
• EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)

  2020cites this paper
• Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр

  2020cites this paper
• Lipoprotein profile and lipid metabolism of PXB-cells®, human primary hepatocytes from liver-humanized mice: proposal of novel in vitro system for screening anti-lipidemic drugs.

  2020cites this paper
• Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

  2020cites this paper
• Solanum nigrum polyphenols reduce body weight and body fat by affecting adipocyte and lipid metabolism.

  2019cites this paper
• Activation of intestinal peroxisome proliferator-activated receptor- (cid:11) increases high-density lipoprotein production.

  2019cites this paper
• Solubility measurement, Hansen solubility parameters and solution thermodynamics of gemfibrozil in different pharmaceutically used solvents

  2019cites this paper
• Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion

  2019cites this paper
• Hepatocyte peroxisome proliferator-activated receptor alpha regulates bile acid synthesis and transport.

  2019cites this paper
• Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence

  2018cites this paper
• Einflüsse von Genistein und Fenofibrat auf den hepatischen Lipidstoffwechsel im in vitro-Modell der Steatosis hepatis

  2018cites this paper
• β-Cell Failure or β-Cell Abuse?

  2018cites this paper
• The impact of propranolol, 17α-ethinylestradiol, and gemfibrozil on early life stages of marine organisms: effects and risk assessment

  2018cites this paper
• Anticancer Properties of Fenofibrate: A Repurposing Use

  2018cites this paper
• Bezafibrate Upregulates Mitochondrial Biogenesis and Influence Neural Differentiation of Human-Induced Pluripotent Stem Cells

  2018cites this paper
• Gemfibrozil reduces lipid accumulation in SMMC-7721 cells via the involvement of PPARα and SREBP1

  2018cites this paper
• The olive constituent oleuropein, as a PPARα agonist, markedly reduces serum triglycerides.

  2018cites this paper
• Fenofibrate Reduces the Asthma-Related Fibroblast-To-Myofibroblast Transition by TGF-Β/Smad2/3 Signaling Attenuation and Connexin 43-Dependent Phenotype Destabilization

  2018cites this paper
• Pharmacological preconditioning with gemfibrozil preserves cardiac function after heart transplantation

  2017cites this paper
• EXAMINING THE DIVERSE CONTRIBUTIONS OF EL TO SYSTEMIC LIPID METABOLISM

  2017cites this paper
• Therapies Targeting HDLc Levels and HDL Function

  2017cites this paper
• Increasing HDL-C levels with medication: current perspectives

  2017cites this paper
• Dilucidando el mecanismo de acción de los fibratos

  2016cites this paper
• A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD

  2016cites this paper
• Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models

  2015cites this paper
• The fibrate gemfibrozil is a NO‐ and haem‐independent activator of soluble guanylyl cyclase: in vitro studies

  2015cites this paper
• Postprandial decrease in LDL-cholesterol in men with metabolic syndrome

  2015cites this paper
• Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study

  2015cites this paper
• The effect of tomato juice supplementation on biomarkers and gene expression related to lipid metabolism in rats with induced hepatic steatosis

  2015cites this paper
• Mulberry leaves (Morus alba L.) ameliorate obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice

  2015cites this paper
• The Effect of Stevia Rebaudiana on Serum Omentin and Visfatin Level in STZ-Induced Diabetic Rats

  2015cites this paper
• Immunometabolism in obese asthma

  2015cites this paper
• BEYOND PEROXISOME: ABCD2 MODIFIES PPARα SIGNALING AND IDENTIFIES A SUBCLASS OF PEROXISOMES IN MOUSE ADIPOSE TISSUE

  2014influential citation
• A Diet with Carbohydrates Eaten Primarily at Dinner: An Innovative, Nutritional Approach to End the Vicious Cycle of Abdominal Obesity

  2014cites this paper
• Upregulation of hepatic VLDLR via PPARα is required for the triglyceride-lowering effect of fenofibrate

  2014cites this paper
• Novel concepts in HDL pharmacology.

  2014cites this paper
• Fenofibrate increases serum vaspin by upregulating its expression in adipose tissue

  2014cites this paper
• [Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].

  2014cites this paper
• L'effet du polymorphisme PPARalpha-L162V sur la réponse lipidique à une supplémentation en acides gras polyinsaturés oméga-3

  2014cites this paper
• Consumption of Ocimum sanctum L. and Citrus paradisi infusions modulates lipid metabolism and insulin resistance in obese rats.

  2014cites this paper
• Total saponins from Rosa laevigata Michx fruit attenuates hepatic steatosis induced by high-fat diet in rats.

  2014cites this paper
• Mechanism of action of anti-hypercholesterolemia drugs and their resistance.

  2014cites this paper
• Role of selective peroxisome proliferator‐activated receptor modulators in managing cardiometabolic disease: tale of a roller‐coaster

  2014cites this paper
• Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.

  2013cites this paper
• [Fibric acid derivatives: focus on fenofibrate].

  2013cites this paper
• Role of PPARα and HNF4α in Stress-Mediated Alterations in Lipid Homeostasis

  2013cites this paper
• Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

  2013cites this paper
• Validated spectrofluorometric method for determination of gemfibrozil in self nanoemulsifying drug delivery systems (SNEDDS).

  2013cites this paper
• Activation of intestinal Peroxisome Proliferator-Activated Receptor α increases HDL production

  2013cites this paper
• Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats.

  2013cites this paper
• Immunometabolism in Obese Asthmatics: Are We There Yet?

  2013cites this paper
• Effects of Verbascoside-Based Diet on Blood and Plasma Constituents of Rabbits

  2013cites this paper
• Biochemical Effects of Some Peroxisome Proliferator Activated Receptor Ligands in Hyperhomocysteinemic-rats

  2013cites this paper
• Dietary modi fi cation of metabolic pathways via nuclear hormone receptors

  2013cites this paper
• Design and optimization of self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil.

  2012cites this paper
• Novel Pleiotropic Effects of Niacin

  2012cites this paper
• The clofibrate saga: a retrospective commentary.

  2012cites this paper
• Dietary modification of metabolic pathways via nuclear hormone receptors

  2012cites this paper
• APOA5 gene expression in the human intestinal tissue and its response to in vitro exposure to fatty acid and fibrate.

  2012cites this paper
• Established and Emerging Approaches for the Management of Dyslipidaemia

  2012cites this paper
• Pravastatin and fenofibrate in combination (Pravafenix®) for the treatment of high-risk patients with mixed hyperlipidemia

  2012cites this paper
• Fibratos: efectos farmacológicos

  2012cites this paper
• AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats

  2012cites this paper
• Role of fatty acids and polyphenols in inflammatory gene transcription and their impact on obesity, metabolic syndrome and diabetes.

  2012cites this paper
• The Interaction of Environmentally Relevant Pollutants with Nuclear Hormone Receptors of European Flounder (Platichthys flesus)

  2012cites this paper
• Fenofibrate

  2012cites this paper
• Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency".

  2012cites this paper
• Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?

  2012cites this paper
• Mechanisms of lipid droplet formation by conjugated linoleic acid (CLA) isomers and its effects on cell viability

  2011cites this paper
• Fenofibrate

  2011cites this paper
• Hyperlipidaemia and cardiovascular disease: do fibrates have a role?

  2011cites this paper
• Fenofibrate

  2011cites this paper
• Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor α (PPARα) activity

  2011cites this paper
• Mulberry water extracts possess an anti-obesity effect and ability to inhibit hepatic lipogenesis and promote lipolysis.

  2011cites this paper
• Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives.

  2011cites this paper
• Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (Danio rerio).

  2011cites this paper
• Aetiological and clinical aspects of symptomatic gallstone disease and pancreatic cancer.

  2011cites this paper
• Discovery of gemfibrozil analogues that activate PPARα and enhance the expression of gene CPT1A involved in fatty acids catabolism.

  2011cites this paper